All data are based on the daily closing price as of May 1, 2026
h
Hisamitsu Pharmaceutical
4530.TSE
38.57 USD
0.66
+1.74%
Overview
Last close
38.57 usd
Market cap
2.72B usd
52 week high
41.89 usd
52 week low
25.59 usd
Target price
27.07 usd
Valuation
P/E
22.4719
Forward P/E
12.2699
Price/Sales
2.6084
Price/Book Value
1.4572
Enterprise Value
1.97B usd
EV/Revenue
1.8952
EV/EBITDA
10.0548
Key financials
Revenue TTM
1.04B usd
Gross Profit TTM
612.16M usd
EBITDA TTM
159.02M usd
Earnings per Share
1.71 usd
Dividend
0.29 usd
Total assets
367.16B usd
Net debt
-106.48B usd
About
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to Asia, the United States, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan. As of February 19, 2026, Hisamitsu Pharmaceutical Co., Inc. operates as a subsidiary of Taiyo Kosan Co., Ltd.